drugset / Trial / NCT02808091
Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell Lymphoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
* Assess responses, progression free survival (PFS) and overall survival (OS) of the combination of GIFOX-B chemotherapy with intensity-modulated radiation therapy (IMRT) in Stage IB or bulky disease - II and without IMRT in Stage III - IV. * Assess the toxicity and maximum tolerated dose of bortezomib administered in combination with GIFOX chemotherapy.
Timeline
- Start
- 2011-03
- Primary completion
- 2013-11
- Completion
- 2014-03
Outcome
Outcome not reported
Stopped (Enrollment): “Slow recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | — | — |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Ifosfamide | Small molecule | — | — |
| Subject | Oxaliplatin | Small molecule | — | — |